source
- Eli Lilly beats forecasts with 56% revenue jump, lifts full-year outlookEli Lilly reported first‑quarter revenue of $19.8 billion, up 56% year over year, and net income of $7.4 billion, or $8.26 a share. Non‑GAAP earnings were $8.55 a share, well above the $6.77 consen…
- BMS's Krazati fails confirmatory colorectal cancer trial, jeopardizing its accelerated approvalBristol Myers Squibb said its drug Krazati did not meet the primary endpoint in a confirmatory study for second‑line colorectal cancer. The trial was required to verify the benefit that earned the…